

Helix BioMedix Adopts Rights Plan

Aug 22, 2003 - Bothell, Washington

BioMedix, Inc. (OTC Bulletin Board: HXBM - News), an early-stage biotechnology company, today announced that its board of directors approved the adoption of a Stockholder Rights Plan pursuant to which all of Helix's stockholders as of September 15, 2003 ("record date") will receive rights to purchase shares of a new series of Preferred Stock.

The Rights Plan is not in response to any particular proposal but is intended as a means to guard against abusive takeover tactics. The Rights Plan is designed to enable all Helix stockholders to realize the full value of their investment and to provide for fair and equal treatment for all stockholders in the event that an unsolicited attempt is made to acquire Helix.

The rights will be distributed as a non-taxable dividend and will expire ten years from the record date. The rights will be exercisable only if a person or group acquires 15% or more of Helix's Common Stock or announces a tender offer for 15% or more of the Common Stock. If a person acquires 15% or more of Helix's Common Stock, all rights holders except the buyer will be entitled to acquire Helix Common stock at a discount. The effect will be to discourage acquisitions of more than 15% of Helix's Common Stock without negotiations with the Board.

The rights will trade with Helix's Common stock, unless and until they are separated upon the occurrence of certain future events. The rights distribution is not taxable to the stockholders. Helix's Board of Directors may terminate the Rights Plan at any time or redeem the rights prior to the time the rights are triggered. Additional details regarding the Rights Plan will be outlined in a summary to be mailed to all stockholders following the record date.

About Helix BioMedix:

Helix BioMedix, Inc. is an early-stage biotechnology company whose mission is to become the industry leader in developing and commercializing bioactive peptides (small proteins). The antimicrobial and wound healing properties of these peptides qualify them for inclusion in a wide range of both pharmaceutical and consumer products. The Company is currently focused on the development of selected peptides as pharmaceutical agents for use in treating cystic fibrosis, sexually-transmitted diseases, and in wound healing. Non-pharmaceutical applications being pursued by Helix BioMedix include adjuvants for cosmetics/cosmeceuticals and wide-spectrum biocides. Located in Bothell, Washington, Helix BioMedix is a product development company organized to derive revenue from licensing its peptide-based technology to partners with sales, marketing, and/or manufacturing expertise. More information about the Company and its proprietary peptides can be found on the Company's website at www.helixbiomedix.com.

Important Notice:

Except for historical information presented in this press release, matters discussed herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the opinions and estimates of management only as of the date of

this release and are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Factors that might cause such a difference include, but are not limited to, uncertainties related to the Company's access to capital, the progress, costs and results of any clinical trials undertaken by the Company, progress of research and development projects, and uncertainties related to whether the Company's product candidates would ultimately achieve commercial success. Reference should be made to Helix BioMedix's public disclosure documents including its Annual Report on Form 10-KSB, filed with the Securities and Exchange Commission for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this press release. Helix BioMedix disclaims any intent or obligation to update these forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

For more information please contact:

R. Stephen Beatty

President and CEO

(425)402-8400

sbeatty@helixbiomedix.com